IPATential150: Phase III Study of Ipatasertib plus Abiraterone vs Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer – Cora Sternberg

PTEN-loss is relatively common in advanced prostate cancer and is associated with worse prognosis as well as reduced benefit from androgen-axis targeting agents. Ipatasertib is a novel oral anti-cancer agent, under investigation in prostate and breast cancers. Orally administered, it is designed to target three isoforms of AKT (protein kinase B), in order to block the PI3 Kinase/AKT signaling…

Read the full article here

Source: UroToday

Categories: General Medicine News, Latest Headlines

Tags: ESMO20, IPATential150, ProstateCancer, WatchNow

Tweets with this article

UroToday.com

Phase III study ipatasertib + abiraterone vs placebo + abiraterone in metastatic castration-resistant #ProstateCancer. @cnsternberg @EngIPM joins @CaPsurvivorship sharing details of the #IPATential150 study, presented at #ESMO20. #WatchNow on UroToday > https://t.co/EfQqeFN2Jz https://t.co/7vdvc799aT

PSMA PET & The Impact of the PRIMARY Trial “Presentation” – Louise Emmett

At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the…

UroToday.com May 8, 2024

Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor – Beyond the Abstract

testicular cancer, Testicular germ cell tumors (TGCTs), non-seminomatous germ cell tumors (NSGCTs), retroperitoneal lymph node dissection (RPLND), non-seminomatous germ cell tumors after chemotherapy.

UroToday.com May 8, 2024

An Analysis in NMIBC Patients – A Comparative Study of White Light and Blue Light Cystoscopy in an Equal Access Setting – Stephen B. Williams

Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance…

UroToday.com May 8, 2024

Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management – Oliver Sartor

Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A.…

UroToday.com May 8, 2024

Radioligand Therapy’s Role in Treating mCRPC – Oliver Sartor

Alicia Morgans engages in a conversation with Oliver Sartor about the evolving landscape of Radioligand Therapy in metastatic castration-resistant prostate cancer (mCRPC). Dr. Sartor discusses…

UroToday.com May 8, 2024

Patient Selection for PSMA Radioligand Therapy – Ephraim Parent

Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr.…

UroToday.com May 8, 2024

Managing Nonmetastatic Castration-Resistant Prostate Cancer – Zachary Reardon

Zach Klaassen and Zach Reardon delve into the nuances of managing nonmetastatic castration-resistant prostate cancer (nmCRPC) in clinical practice. Dr. Reardon discusses the evolving landscape…

UroToday.com May 8, 2024

State of the Art and Future Challenges of Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer: A Systematic Review of Literature – Beyond the Abstract

Prostate cancer, stereotactic body radiotherapy (SBRT), Urethra-Sparing Stereotactic Body Radiotherapy, Urethra-Sparing Stereotactic Body Radiotherapy for Prostate Cancer, magnetic resonance guided radiotherapy (MRgRT).

UroToday.com May 7, 2024

Comparing Cost-Effectiveness of Surgery, Radiation, and Chemo for Seminoma – Daniel Joyce

Ruchika Talwar interviews Daniel Joyce about his journey into cost-effectiveness studies, particularly in testicular cancer. Initially skeptical, Dr. Joyce now sees these studies as crucial…

UroToday.com May 7, 2024

ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club – Rashid Sayyid & Zachary Klaassen

Rashid Sayyid and Zach Klaassen delve into the significance of racial disparities in prostate cancer treatment through a subgroup analysis of the ARASENS trial, which…

UroToday.com May 7, 2024

Related Articles